JP2019504031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504031A5 JP2019504031A5 JP2018533051A JP2018533051A JP2019504031A5 JP 2019504031 A5 JP2019504031 A5 JP 2019504031A5 JP 2018533051 A JP2018533051 A JP 2018533051A JP 2018533051 A JP2018533051 A JP 2018533051A JP 2019504031 A5 JP2019504031 A5 JP 2019504031A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- gpv
- bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000032843 Hemorrhage Diseases 0.000 claims 12
- 230000000740 bleeding effect Effects 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 9
- 101000926072 Varicella-zoster virus (strain Dumas) Envelope glycoprotein C Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 239000000701 coagulant Substances 0.000 claims 4
- 102100038411 Platelet glycoprotein V Human genes 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 101001033026 Homo sapiens Platelet glycoprotein V Proteins 0.000 claims 2
- 208000013544 Platelet disease Diseases 0.000 claims 2
- 101710195077 Platelet glycoprotein V Proteins 0.000 claims 2
- 208000014759 blood platelet disease Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 230000003471 anti-radiation Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000004023 fresh frozen plasma Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003634 thrombocyte concentrate Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202582.1 | 2015-12-23 | ||
| EP15202582.1A EP3184544A1 (en) | 2015-12-23 | 2015-12-23 | Glycoprotein v inhibitors for use as coagulants |
| PCT/EP2016/082572 WO2017109180A1 (en) | 2015-12-23 | 2016-12-23 | Glycoprotein v inhibitors for use as coagulants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504031A JP2019504031A (ja) | 2019-02-14 |
| JP2019504031A5 true JP2019504031A5 (https=) | 2020-01-16 |
Family
ID=55085479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533051A Pending JP2019504031A (ja) | 2015-12-23 | 2016-12-23 | 血液凝固剤として使用するための糖タンパク質ｖ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190169307A1 (https=) |
| EP (2) | EP3184544A1 (https=) |
| JP (1) | JP2019504031A (https=) |
| KR (1) | KR20180095083A (https=) |
| CN (1) | CN108473581A (https=) |
| AU (1) | AU2016375162A1 (https=) |
| CA (1) | CA3008198A1 (https=) |
| WO (1) | WO2017109180A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4637920A1 (en) | 2022-12-22 | 2025-10-29 | Julius-Maximilians-Universität Würzburg | Antibodies for use as coagulants |
| CN116375859A (zh) * | 2023-06-05 | 2023-07-04 | 北京大学第一医院 | 一种抗vWF/PF4蛋白的单克隆抗体及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2166872A1 (en) * | 1993-07-09 | 1995-01-19 | Francois Lanza | Platelet glycoprotein v gene and uses |
| US6083688A (en) * | 1993-07-09 | 2000-07-04 | Cor Therapeutics, Inc | Platelet glycoprotein V gene and uses |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1102840A2 (en) * | 1998-08-04 | 2001-05-30 | Cor Therapeutics, Inc. | Transgenic animals having a modified glycoprotein v gene |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| WO2000068377A1 (en) * | 1999-05-07 | 2000-11-16 | Merck Patent Gmbh | Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
-
2015
- 2015-12-23 EP EP15202582.1A patent/EP3184544A1/en not_active Withdrawn
-
2016
- 2016-12-23 JP JP2018533051A patent/JP2019504031A/ja active Pending
- 2016-12-23 WO PCT/EP2016/082572 patent/WO2017109180A1/en not_active Ceased
- 2016-12-23 CA CA3008198A patent/CA3008198A1/en not_active Abandoned
- 2016-12-23 EP EP16826340.8A patent/EP3394101A1/en not_active Withdrawn
- 2016-12-23 US US16/065,300 patent/US20190169307A1/en not_active Abandoned
- 2016-12-23 AU AU2016375162A patent/AU2016375162A1/en not_active Abandoned
- 2016-12-23 KR KR1020187021268A patent/KR20180095083A/ko not_active Withdrawn
- 2016-12-23 CN CN201680075538.6A patent/CN108473581A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LeMessurier et al. | Respiratory barrier as a safeguard and regulator of defense against influenza A virus and Streptococcus pneumoniae | |
| Balagholi et al. | Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy | |
| Heinbockel et al. | Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors | |
| JP2018193377A5 (https=) | ||
| Pires et al. | Hyper‐inflammation and complement in COVID‐19 | |
| Cong et al. | Plasma membrane wounding and repair in pulmonary diseases | |
| JP2015529225A5 (https=) | ||
| JP2010285439A5 (https=) | ||
| HRP20220355T1 (hr) | Postupci za liječenje infekcija coronaviridae | |
| JP2015512406A5 (https=) | ||
| FI4374873T3 (fi) | Aine käytettäväksi silmäsairauksien hoidossa tai ehkäisyssä | |
| JP2016512218A5 (https=) | ||
| JP2016529255A5 (https=) | ||
| JP2015534562A5 (https=) | ||
| JP2015502389A5 (https=) | ||
| JP2015517488A5 (https=) | ||
| GB2462228A (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| BR112014007223A2 (pt) | derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos | |
| JP2011527301A5 (https=) | ||
| JP2015511625A5 (https=) | ||
| JP2015512927A5 (https=) | ||
| JP2015513535A5 (https=) | ||
| JP2019504031A5 (https=) | ||
| Amoafo et al. | Platelet P2Y12 signalling pathway in the dysregulated immune response during sepsis |